Shilpa opens bioconjugation site

Indian CDMO Shilpa Biologicals has opened a dedicated bioconjugation alongside its commercial biologics manufacturing facility in Dharwad. This is currently undergoing validation and is expected to begin onboarding client programmes by September.

The new suite is built to support the manufacture of antibody-drug conjugates (ADCs) and other advanced bioconjugates. It includes 200L single-use bioconjugation reactors and a lyophilisation capacity of up to 65 kg. There will also be development laboratories for process development, analytical characterisation, and both early and late-stage scale-up capabilities. 

Shilpa noted that this will place it among the small group of CDMOs able to supply clinical- and commercial-scale manufacturing across all three components of ADCs: payloads and linkers, monoclonal antibodies and bioconjugation. It claims one of the industry’s largest payload and linker libraries, plus multi-ton high-potency API capacity.